Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsmedMEX:INSM 69 5-Day RSI is 3.08 as of Jul. 21, 2026. GuruFocus rates MEX:INSM with a GF Score™ of 69/100 and a GF Value™ of MXN3,329.86 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,421 Biotechnology companies, Insmed ranks better than 61.15% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-21), Insmed's 5-Day RSI is 3.08.
The industry rank for Insmed's 5-Day RSI or its related term are showing as below:
MEX:INSM's 5-Day RSI is ranked better than 61.15% of 1421
companies
in the Biotechnology industry
Industry Median: 38.41
vs MEX:INSM: 3.08
Insmed (MEX:INSM) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Insmed 5-Day RSI Related Terms
MEX:INSM vs INCY, BNTX, ROIV: 5-Day RSI Comparison
For the Biotechnology subindustry, Insmed's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed 5-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Insmed's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (MEX:INSM) has a 5-Day RSI of 3.08 as of Jul. 21, 2026. According to the industry distribution chart, Insmed ranks #552 out of 1421 companies in the Biotechnology industry, placing it in the top 38.8%.
Is Insmed's 5-Day RSI too high?
Insmed's current 5-Day RSI is 3.08. The Biotechnology industry median 5-Day RSI is 38.41. Insmed's value of 3.08 is 92% below this industry median. Based on the distribution chart, Insmed ranks #552 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Insmed has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's 5-Day RSI compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #552 out of 1421 companies for 5-Day RSI. This puts Insmed in the upper half of its industry. The industry median 5-Day RSI is 38.41. Insmed's value of 3.08 is 92% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Biotechnology company?
The median 5-Day RSI among Biotechnology companies is 38.41, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insmed's current 5-Day RSI of 3.08 is 92% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 5-Day RSI is 38.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insmed's current 5-Day RSI is 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MEX:INSM) is currently considered Possible Value Trap. The stock's GF Value™ is MXN3,329.86, compared to a current price of MXN1,981.33 — trading 40.5% below its estimated fair value. The current 5-Day RSI is 3.08 and 92% below the Biotechnology industry median of 38.41. Insmed's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Insmed (MEX:INSM), the current 5-Day RSI is 3.08 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN1,981.33 is trading 40.5% below its estimated GF Value™ of MXN3,329.86.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for MEX:INSM:
5-Day RSI: 3.08
GF Value™: MXN3,329.86 vs. price of MXN1,981.33 (40.5% below fair value)
Industry Position: 92% below the Biotechnology median (#552 of 1421)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
69GF Score
Get the complete analysis for MEX:INSM
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
